Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis

Digestion

Volumn 80, Issue 1, 2009, Pages 30-35

  Mañosa, Míriam ^a   López San Román, Antonio ^b   Garcia Planella, Esther ^c,h   Bastida, Guillermo ^d,h   Hinojosa, Joaquín ^e   Gonzalez Lama, Yago ^f   Masnou, Helena ^g   Domènech, Eugeni ^a,h  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL DE SAGUNTO   (Spain)

^f HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^g HOSPITAL SANTA CATERINA   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Colectomy; Cyclosporin; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; INFLIXIMAB; MESALAZINE; PREDNISOLONE; STEROID;

ADULT; ARTICLE; BACTERIAL ARTHRITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COLON RESECTION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; MAINTENANCE THERAPY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REFRACTORY PERIOD; RELAPSE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 65549113070     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000212075     Document Type: Article

References (19)

1. Edwards FC, Truelove SC: The course and prognosis of ulcerative colitis. Gut 1963;4: 299-315.
2. Truelove SC, Willoughby CP, Lee EG, Kettlewell MG: Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;ii:1086-1088.
3. Travis SPL, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MGW, Jewell DP: Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-910.
4. Lichtenstein GR, Cohen R, Yamashita B, Diamond RH: Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J Clin Gastroenterol 2006;40:669-677.
5. Waljee A, Waljee J, Morris AM, Higgins PD: Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006;55: 1575-1580.
6. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845.
7. García-López S, Gomollón-García F, Pérez-Gisbert J: Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005; 28: 607-614.
8. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K: Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; 1: CD004277.
9. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
10. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Grä C, Vilien M, Ström M, Danielsson A, Verbaan H, Hell-ström PM, Magnuson A, Curman B: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-1811.
11. Domènech E, Garcia-Planella E, Bernal I, Rosinach M, Cabré E, Fluvia L, Boix J, Gassull MA: Azathioprine without oral cyclo-sporine in the long-term maintenance of remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Aliment Ther Pharmacol 2002;16:2061-2065.
12. Domènech E, Gomollón F, Obrador A, Panés J, Gassull MA: Is oral ciclosporin necessary to switch from i.v. to thiopurines? Aliment Pharmacol Ther 2006;23:555-556.
13. Silverberg M, Satsangi J, Ahmad T, Arnott IDR, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(suppl A):5A-36A.
14. Gomes P, du Boulay C, Smith CL, Holdstock G: Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27:92-95.
15. Maser EA, Villela R, Silverberg MS, Greenberg GR: Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:1248-1254.
16. Ptachcinski RJ, Venkataramanan R, Burckart GJ, Gray JA, Van Thiel DH, Sanghvi A, Rosenthal JT: Cyclosporine kinetics in healthy volunteers. J Clin Pharmacol 1987; 27: 243-248.
17. Lam EC, Bailey RJ: Infliximab salvage therapy after cyclosporine in an acute flare of chronic ulcerative colitis. Can J Gastroenterol 2003;17:198-200.
18. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A: Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008;6:1112-1116.
19. Leblanc S, Allez M, Seksik P, Flourié B, Peeters H, Dupas J, Bouguen G, Peyrin-Bi-roulet L, Bourreille A, Dewit O, Bouhnik Y, Michetti P, Chaussade S, Saussure P, Colombel J, Lémann M: Successive treatment with cyclosporine and infliximab of severe ulcerative colitis. Gut 2008; 57(suppl II):A66.